Skip to content


  • Retraction Note
  • Open Access

Retraction Note: therapeutic stimulation of GLP-1 and GIP protein with DPP-4 inhibitors for type-2 diabetes treatment

  • 1Email author,
  • 1,
  • 1 and
  • 1
Journal of Diabetes & Metabolic Disorders201615:34

  • Received: 5 August 2016
  • Accepted: 11 August 2016
  • Published:

The original article was published in Journal of Diabetes & Metabolic Disorders 2015 14:15

The Editors are retracting this article [1] due to overlap with previous publications, most notably [2, 3]. We apologise for any inconvenience caused. We have been unable to contact the authors regarding the retraction of their article.



Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

School of Biotechnology, Rajiv Gandhi Proudyogiki Vishwavidyalaya (State Technological University of Madhya Pradesh), Bhopal, India


  1. Sharma A, Paliwal G, Upadhyay N, Tiwari A. Therapeutic stimulation of GLP-1 and GIP protein with DPP-4 inhibitors for type-2 diabetes treatment. J Diab Metabol Disord. 2015;14:15.View ArticleGoogle Scholar
  2. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care. 2003;26:2929–40.View ArticlePubMedGoogle Scholar
  3. Kountz D. The dipeptidyl peptidase (DPP)-4 inhibitors for type 2 diabetes mellitus in challenging patient groups. Adv Ther. 2013;30:1067–85.View ArticlePubMedPubMed CentralGoogle Scholar


© The Author(s). 2016